What is Sunshine Heart's lead device?
Sunshine Heart's lead device is the C-Pulse® Heart Assist System, an implantable, non-blood contacting, heart assist therapy for the treatment of moderate to severe heart failure which can be implanted using a minimally invasive procedure. Analysts who cover the cardiovascular market and follow Sunshine Heart have estimated the conservative market for the C-Pulse device is in excess of $2.5 billion. Others have already written in detail about the science behind the C-Pulse technology, and can be accessed here, here, and here.
Why is Jude trading low?
Jude is trading near 9 year lows on continued safety concerns beleaguering the company. An FDA inspection discovered significant problems with the company's testing and oversight of the Durata, an electrical wire that connects an implanted defibrillator to a patient's heart.
Is HeartWare a destination therapy?
The firm further contends that there is now a greater chance that HeartWare's device will not be approved as a destination therapy. Here is where Sunshine Heart comes to the rescue, as the company's technology would perfectly complement one of these major players.
Is Sunshine Heart a good fit for the market?
The market has been richly rewarding companies that engage in strategic acquisitions, as I will detail below. Sunshine Heart is an ideal fit for one of the big players in the industry, and the cheapest in the space. Based on the recent flurry of M&A in the sector, the insanely low valuation of Sunshine Heart, and the recent setbacks of other companies in the sector, I fully expect one of the big players to swoop in and offer to purchase Sunshine Heart at a hefty premium.
Is Sunshine Heart a biotech company?
Sunshine Heart has the risks typical of early stage biotech/medical device companies. These include clinical risk, device failure, and equity dilution (though Sunshine has sufficient operating capital for the foreseeable future). Sunshine will likely need one additional capital raise on the chance it remains independent through the completion of the pivotal trial. However, in my mind, it would be much more economical for a company like HeartWare to pony up $20-30 million for the trial, rather than wait and spend $1.5 billion for the company after-the-fact.
What is Sunshine Heart Aid?
The company was formed to work on developing a medical device to treat moderate to severe heart failure conditions . Heart disease is the major cause of death in our country, so new and innovative treatment options are needed. The product that Sunshine was developing is known as the C-Pulse Assist System that works as a counter-pulsation in the heart. This simply means their system involved placing a cuff around the outside of the aorta, where the assist system would inflate and deflate the cuff, thus impacting the rhythm with the natural heartbeat. It was Sunshine's management belief that by applying a "secondary pulse" this would increase the heart's function in a person suffering from a condition were optimal functioning of their heart was declining.
Does a heart disease cause shortness of breath?
Basically, a diseased heart would not have to work as hard in the process of pumping blood through the body. If this could be accomplished it was felt this would also impact heart symptoms like shortness of breath, dizziness, fluid retention, and a patient's ability to do normal day-to-day activities.
Signals & Forecast
Sunshine Biopharma, Inc. has increased volume and follows the last lift in the price. This is considered to be a technical positive sign as volume should follow the price-formation. The very low volume increases the risk and reduces the other technical signals issued.
Support, Risk & Stop-loss
Sunshine Biopharma, Inc. finds support from accumulated volume at $0.0493 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Is Sunshine Biopharma, Inc. stock A Buy?
Sunshine Biopharma, Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Insiders are positive buying more shares than they are selling in Sunshine Biopharma, Inc
In the last 49 trades there were 1.06 billion shares bought and 297.43 million shares sold. The last trade was done 395 days ago by Sebaaly Camille who bough 20 million shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
About Sunshine Biopharma, Inc
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the development of anticancer drugs.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
